Professor Svetlana Grigoryan

Yerevan State Medical University after M. Heratsi, Yerevan (Armenia)

Contributor content

$Comparative assessment of the features of atrial fibrillation occurrence in heart failure patients with preserved and mildly reduced ejection fraction$

Presentation

Comparative assessment of the features of atrial fibrillation occurrence in heart failure patients with preserved and mildly reduced ejection fraction

Presentation

Preventive role of angiotensin receptor blockers on the recurrent AF in hypertensive patients

Presentation

The features of atrial fibrillation occurrence in patients who have undergone COVID-19

Presentation

The identification of predictors and characteristics of the course of ACS in patients undergoing COVID-19

$Coagulation cascade, inflammatory and fibrosis markers in patients with preserved ejection fraction heart failure and AF$

Presentation

Coagulation cascade, inflammatory and fibrosis markers in patients with preserved ejection fraction heart failure and AF

Presentation

Stroke in atrial fibrillation: inflammation as additional risk (retrospective study)

Presentation

The role of some additional risk factors in the occurrence of paroxysmal / persistent atrial fibrillation in patients with arterial hypertension

$The role of inflammation and fibrosis in the occurrence of atrial fibrillation in heart failure patients with mid-range ejection fraction$

Presentation

The role of inflammation and fibrosis in the occurrence of atrial fibrillation in heart failure patients with mid-range ejection fraction

Presentation

Coagulation cascade, inflammatory and fibrosis markers in patients with paroxysmal/persistent atrial fibrillation

Presentation

The relationships between heart rate variability, inflammation and fibrosis markers in patients with atrial fibrillation

Explore sponsored resources

Professor Svetlana Grigoryan

Contributor content

Comparative assessment of the features of atrial fibrillation occurrence in heart failure patients with preserved and mildly reduced ejection fraction

Preventive role of angiotensin receptor blockers on the recurrent AF in hypertensive patients

The features of atrial fibrillation occurrence in patients who have undergone COVID-19

The identification of predictors and characteristics of the course of ACS in patients undergoing COVID-19

Coagulation cascade, inflammatory and fibrosis markers in patients with preserved ejection fraction heart failure and AF

Stroke in atrial fibrillation: inflammation as additional risk (retrospective study)

The role of some additional risk factors in the occurrence of paroxysmal / persistent atrial fibrillation in patients with arterial hypertension

The role of inflammation and fibrosis in the occurrence of atrial fibrillation in heart failure patients with mid-range ejection fraction

Coagulation cascade, inflammatory and fibrosis markers in patients with paroxysmal/persistent atrial fibrillation

The relationships between heart rate variability, inflammation and fibrosis markers in patients with atrial fibrillation

ESC 365 is supported by